These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

857 related items for PubMed ID: 31676731

  • 21. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
    Jois B, Asopa R, Basu S.
    Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
    [Abstract] [Full Text] [Related]

  • 22. Influence of lanreotide on uptake of 68Ga-DOTATATE in patients with neuroendocrine tumours: a prospective intra-patient evaluation.
    Aalbersberg EA, de Wit-van der Veen BJ, Versleijen MWJ, Saveur LJ, Valk GD, Tesselaar MET, Stokkel MPM.
    Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):696-703. PubMed ID: 30097670
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.
    Johnbeck CB, Knigge U, Loft A, Berthelsen AK, Mortensen J, Oturai P, Langer SW, Elema DR, Kjaer A.
    J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
    [Abstract] [Full Text] [Related]

  • 25. A frequency and semiquantitative analysis of pathological 68Ga DOTATATE PET/CT uptake by primary site-dependent neuroendocrine tumor metastasis.
    Kunikowska J, Pawlak D, Kolasa A, Mikołajczak R, Królicki L.
    Clin Nucl Med; 2014 Oct; 39(10):855-61. PubMed ID: 25072928
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Comparison of somatostatin receptor agonist and antagonist for peptide receptor radionuclide therapy: a pilot study.
    Wild D, Fani M, Fischer R, Del Pozzo L, Kaul F, Krebs S, Fischer R, Rivier JE, Reubi JC, Maecke HR, Weber WA.
    J Nucl Med; 2014 Aug; 55(8):1248-52. PubMed ID: 24963127
    [Abstract] [Full Text] [Related]

  • 28. The usefulness of [68 Ga]Ga-DOTA-JR11 PET/CT in patients with meningioma: comparison with MRI.
    Wang P, Liu S, Li X, Liu X, Li S, Wu Z, Cheng X.
    Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):218-225. PubMed ID: 37682301
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Safety, Biodistribution, and Radiation Dosimetry of 68Ga-OPS202 in Patients with Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Phase I Imaging Study.
    Nicolas GP, Beykan S, Bouterfa H, Kaufmann J, Bauman A, Lassmann M, Reubi JC, Rivier JEF, Maecke HR, Fani M, Wild D.
    J Nucl Med; 2018 Jun; 59(6):909-914. PubMed ID: 29025985
    [Abstract] [Full Text] [Related]

  • 34. Long-Acting Somatostatin Analog Therapy Differentially Alters 68Ga-DOTATATE Uptake in Normal Tissues Compared with Primary Tumors and Metastatic Lesions.
    Ayati N, Lee ST, Zakavi R, Pathmaraj K, Al-Qatawna L, Poon A, Scott AM.
    J Nucl Med; 2018 Feb; 59(2):223-227. PubMed ID: 28729431
    [Abstract] [Full Text] [Related]

  • 35. Differences in tumor-to-normal organ SUV ratios measured with 68 Ga-DOTATATE PET compared with 177 Lu-DOTATATE SPECT in patients with neuroendocrine tumors.
    Wong KK, Frey KA, Niedbala J, Kaza RK, Worden FP, Fitzpatrick KJ, Dewaraja YK.
    Nucl Med Commun; 2022 Aug 01; 43(8):892-900. PubMed ID: 35703269
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Aug 01; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 43.